Ms. Blumstock has over 25 years of venture capital and private equity experience, spanning early to late-stage investments in life sciences and biotechnology. She founded Diamond Therapeutics with the goal of developing much needed and accessible treatments for mental health. Previously, she was the executive director of corporate development at Toronto Innovation Acceleration Partners (TIAP), formerly known as MaRS Innovation. TIAP specializes in venture building for early-stage health science technologies and takes leading-edge research from discovery to market. Before this, Ms. Blumstock was a principal with Genesys Capital, one of the largest Canadian-based venture-capital firms focused exclusively on the life sciences industry. She was a partner with RBC Capital Partners life sciences fund. Ms. Blumstock was also the director of biological and pharmaceutical research at Drug Royalty Corporation (now DRI Capital Inc.), which provides financial solutions in exchange for royalties to health-related organizations worldwide. Ms. Blumstock completed an MBA in finance from Columbia Business School in New York. Her BSc in biology is from the University of Toronto.